NCT02077114View on ClinicalTrials.gov

Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

September 30, 2014

Conditions
Malignant Melanoma With Metastasis
Interventions
BIOLOGICAL

Vaccine consisting of a peptide derived from the protein IDO

All patients will receive seven vaccines containing IDOlong

Trial Locations (1)

2730

Department of Oncology, Herlev Hospital, Herlev

All Listed Sponsors
lead

Herlev Hospital

OTHER

NCT02077114 - Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma | Biotech Hunter | Biotech Hunter